标题
Cardiovascular safety and benefits of GLP-1 receptor agonists
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 16, Issue 3, Pages 351-363
出版商
Informa UK Limited
发表日期
2017-01-20
DOI
10.1080/14740338.2017.1281246
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
- (2016) Rury R. Holman et al. AMERICAN HEART JOURNAL
- Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
- (2016) Keith C. Ferdinand et al. Cardiovascular Diabetology
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk
- (2016) DIABETES CARE
- Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
- (2016) Preman Kumarathurai et al. DIABETES CARE
- Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial
- (2016) Mark M Smits et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
- (2015) Francesco Zaccardi et al. ANNALS OF INTERNAL MEDICINE
- The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
- (2015) Sanjoy K Paul et al. Cardiovascular Diabetology
- Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
- (2015) Rafael Simó et al. Cardiovascular Diabetology
- Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
- (2015) Lawrence Blonde et al. Cardiovascular Diabetology
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
- (2015) Jeanne S. Geiser et al. CLINICAL PHARMACOKINETICS
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
- (2015) Juris J. Meier et al. DIABETES CARE
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2015) Feng Sun et al. Diabetes Technology & Therapeutics
- Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
- (2015) Michael A. Nauck et al. DIABETOLOGIA
- An overview of new GLP-1 receptor agonists for type 2 diabetes
- (2015) Brian Tomlinson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
- (2015) Christoph Kapitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
- (2015) Chin-Hsiao Tseng et al. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
- (2015) Darleen A. Sandoval et al. PHYSIOLOGICAL REVIEWS
- Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
- (2015) Miles Fisher et al. Lancet Diabetes & Endocrinology
- Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes
- (2014) Antonio Ceriello et al. DIABETES CARE
- Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes
- (2014) Julie A. Lovshin et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- (2014) Michael Nauck et al. DIABETES CARE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities
- (2014) Asger Lund et al. European Journal of Internal Medicine
- Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer
- (2014) Thor Chalmer et al. Expert Opinion On Drug Safety
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
- (2014) Keith C. Ferdinand et al. HYPERTENSION
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
- (2014) Robert R. Henry et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide
- (2014) Malcolm A. Young et al. POSTGRADUATE MEDICINE
- A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)
- (2014) Anders Jorsal et al. BMJ Open
- Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2013) Lesley J. Scott BIODRUGS
- Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
- (2013) M. M. Umapathysivam et al. DIABETES
- Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males
- (2013) Jeppe Skov et al. Endocrine Connections
- Reductions in lipids and CV risk markers in patients with type 2 diabetes treated with liraglutide: a meta-analysis
- (2012) J. Plutzky et al. Canadian Journal of Diabetes
- The Glucagon-Like Peptide-1 Receptor—or Not?
- (2012) Charles Pyke et al. ENDOCRINOLOGY
- Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
- (2012) Feng Sun et al. Experimental Diabetes Research
- GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
- (2012) Maria J Jespersen et al. Expert Opinion on Drug Metabolism & Toxicology
- The effect of glucagon-like peptide 1 on cardiovascular risk
- (2012) Jacob Sivertsen et al. Nature Reviews Cardiology
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
- (2011) Robert Ratner et al. Cardiovascular Diabetology
- A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans
- (2011) Philip A. Read et al. Circulation-Cardiovascular Interventions
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- Lixisenatide for type 2 diabetes mellitus
- (2011) Mikkel Christensen et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study
- (2011) Magnus T Jensen et al. European Journal of Preventive Cardiology
- Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies
- (2010) Robert Chilton et al. AMERICAN JOURNAL OF MEDICINE
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
- (2010) Mark Fineman et al. CLINICAL PHARMACOKINETICS
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
- (2010) Wolfgang Glaesner et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
- (2010) Lotte Bjerre Knudsen et al. ENDOCRINOLOGY
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
- (2008) T MORETTO et al. CLINICAL THERAPEUTICS
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes
- (2008) Jessica E. Matthews et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now